Table 1.
Demographic, clinical, pathological and scintigraphic data of the enrolled patients
| Patienta | Gender | Age (years) | Nodule size (mm) | TI-RADS classb | Bethesda classc | Histology | Visual analysis patternd | Washout index | Translocations | Mutations | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PAX8/PPARγ | RET/PTC | BRAF | KRAS | NRAS | HRAS | |||||||||||
| Exons 2 and 3 | Exon 2 | Exon 3 | Exon 2 | Exon 3 | ||||||||||||
| 1 | M | 56 | 24 | 4B | IV | FTC | 3 | −6.5 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 2 | F | 71 | 28 | 4B | IV | FTC | 3 | −5 | Positive | Negative | WT | WT | WT | WT | WT | WT |
| 3 | M | 42 | 18 | 4B | IV | FTC | 3 | 0 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 4 | M | 35 | 26 | 4B | IV Hürthle cell | FTC Hürthle cell | 3 | −6 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 5 | F | 61 | 45 | 4B | IV Hürthle cell | FTC Hürthle cell | 3 | −4 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 6 | F | 22 | 12 | 5 | IV | PTC | 2 | −7 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 7 | F | 43 | 44 | 4B | IV Hürthle cell | FTC Hürthle cell | 2 | −4 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 8 | M | 57 | 31 | 4B | III | FTC | 3 | −8 | Negative | Negative | WT | WT | WT | Q61R | WT | WT |
| 9 | F | 34 | 36 | 4B | IV Hürthle cell | FTC Hürthle cell | 3 | −2 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 10 | F | 59 | 25 | 5 | IV | PDTC | 3 | −2 | Negative | Negative | WT | WT | WT | Q61R | WT | WT |
| 11 | M | 58 | 50 | 4B | IV Hürthle cell | FTC Hürthle cell | 2 | −9 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 12 | F | 47 | 15 | 5 | IV | PTC-FV | 2 | −7.2 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 13 | M | 65 | 21 | 4B | IV | FTC | 2 | −4.1 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 14 | M | 22 | 11 | 4B | IV | PTC-FV | 3 | −4 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 15 | F | 36 | 25 | 4B | IV | PTC | 2 | −7 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 16 | M | 59 | 12 | 5 | IV | PTC | 3 | −2 | Negative | Negative | WT | WT | WT | Q61R | WT | WT |
| 17 | F | 29 | 22 | 5 | IV Hürthle cell | AF Hürthle cell | 3 | −6.5 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 18 | M | 43 | 20 | 4B | IV | AF | 2 | −22 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 19 | F | 32 | 32 | 4B | IV | Hyperplasia | 2 | −18 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 20 | M | 67 | 19 | 4B | IV | AF | 2 | −22 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 21 | F | 51 | 27 | 4B | IV | AF | 1 | −26 | Negative | Negative | WT | WT | WT | Q61R | WT | WT |
| 22 | F | 55 | 12 | 4B | IV | AF | 2 | −23 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 23 | F | 29 | 18 | 4B | IV | AF | 1 | −20 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 24 | F | 48 | 43 | 4B | IV | AF | 2 | −18 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 25 | M | 37 | 22 | 4B | IV | AF | 1 | −26 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 26 | F | 38 | 44 | 4B | IV | AF | 2 | −18 | Negative | Negative | WT | NV | WT | WT | NV | NV |
| 27 | M | 27 | 25 | 4B | IV | AF | 2 | −24 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 28 | F | 46 | 32 | 4B | IV | AF | 2 | −20 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 29 | F | 33 | 17 | 4B | IV | Hyperplasia | 1 | −19 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 30 | F | 46 | 46 | 4B | IV | AF | 2 | −22 | Negative | Negative | WT | WT | WT | WT | NV | WT |
| 31 | F | 69 | 12 | 4B | IV | AF | 2 | −25 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 32 | F | 53 | 24 | 4B | IV | AF | 2 | −19 | Positive | Negative | WT | WT | WT | WT | NV | NV |
| 33 | F | 49 | 11 | 4B | IV | AF | 2 | −16 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 34 | F | 62 | 32 | 4B | IV | AF | 2 | −18 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 35 | F | 48 | 41 | 4B | IV | AF | 1 | −25 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 36 | F | 34 | 23 | 4B | IV | AF | 2 | −27 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 37 | F | 57 | 18 | 4B | IV | AF | 2 | −25 | Positive | Negative | WT | WT | WT | WT | WT | WT |
| 38 | F | 28 | 15 | 4B | IV | AF | 2 | −22 | Negative | Negative | WT | WT | WT | WT | WT | Q61R |
| 39 | F | 81 | 31 | 4B | IV Hürthle cell | AF Hürthle cell | 3 | −8 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 40 | F | 53 | 18 | 4B | IV Hürthle cell | AF Hürthle cell | 2 | −14 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 41 | F | 49 | 12 | 4B | IV | AF | 2 | −26 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 42 | F | 35 | 32 | 4B | IV | AF | 2 | −12 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 43 | F | 43 | 20 | 4B | IV | Hyperplasia | 1 | −27 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 44 | F | 27 | 30 | 4B | IV | Hyperplasia | 1 | −19 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 45 | F | 64 | 18 | 4B | IV | AF | 2 | −20 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 46 | F | 43 | 27 | 4B | IV | AF | 2 | −20 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 47 | M | 39 | 15 | 4B | IV | AF | 1 | −19 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 48 | M | 67 | 11 | 4B | IV | AF | 2 | −22 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 49 | F | 46 | 22 | 4B | IV | AF | 2 | −25 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 50 | M | 33 | 32 | 5 | IV | AF | 2 | −24 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 51 | F | 41 | 14 | 4B | IV | AF | 1 | −18 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 52 | F | 52 | 28 | 4B | IV | AF | 2 | −20 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 53 | F | 55 | 22 | 4B | IV | Hyperplasia | 1 | −19 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 54 | F | 31 | 43 | 4B | IV | AF | 2 | −22 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 55 | F | 62 | 32 | 4B | IV | AF | 2 | −25 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 56 | F | 19 | 19 | 4B | IV | AF | 1 | −18 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 57 | F | 43 | 48 | 4B | IV | AF | 2 | −24 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 58 | M | 27 | 24 | 5 | IV | AF | 2 | −20 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 59 | F | 42 | 17 | 4B | IV | AF | 1 | −25 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 60 | F | 57 | 21 | 4B | IV | AF | 2 | −22 | Negative | Negative | WT | WT | WT | WT | WT | WT |
| 61 | M | 40 | 32 | 4B | IV | AF | 2 | −20 | Negative | Negative | WT | WT | WT | WT | WT | WT |
FTC follicular thyroid carcinoma, PTC papillary thyroid carcinoma, PDTC poorly differentiated thyroid carcinoma, FV follicular variant, WT wild type, NV novel variant
aIn patients 1–16 the nodules were malignant
bTI-RADS classification: 1 normal, 2 benign, 3 probably benign, 4A undetermined pattern, 4B suspicious pattern, 5 consistent with malignancy
cFNAC cytological samples scored according to the Bethesda system: class I nondiagnostic, class II benign, class III indeterminate/atypical, class IV (suspicious for) follicular neoplasm, class V suspicious for malignancy, class VI malignant
dMIBI thyroid images scored visually: pattern 1 no increased uptake of 99mTc-MIBI within the nodule in comparison to the 99mTc-pertechnetate scan on either the early or delayed image, pattern 2 increased uptake on the early image that had decreased on the delayed image, pattern 3 increased uptake on the early image that remained unchanged or had further increased on the delayed image